-
Product Insights
NewNet Present Value Model: Candel Therapeutics Inc’s ProstAtak
Empower your strategies with our Net Present Value Model: Candel Therapeutics Inc's ProstAtak report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – FOG-001 in Gastroesophageal (GE) Junction Carcinomas
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - FOG-001 in Gastroesophageal (GE) Junction Carcinomas report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. FOG-001 in Gastroesophageal (GE) Junction Carcinomas Drug Details: FOG-001...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TAVO-412 in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TAVO-412 in Non-Small Cell Lung Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TAVO-412 in Non-Small Cell Lung Cancer Drug Details: TAVO-412...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Aglatimagene Besadenovec in Pancreatic Ductal Adenocarcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Aglatimagene Besadenovec in Pancreatic Ductal Adenocarcinoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Aglatimagene Besadenovec in Pancreatic Ductal Adenocarcinoma Drug Details: Aglatimagene...
-
Product Insights
NewNet Present Value Model: Novartis AG’s Iscalimab
Empower your strategies with our Net Present Value Model: Novartis AG's Iscalimab report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CAN-3110 in High-Grade Glioma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CAN-3110 in High-Grade Glioma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CAN-3110 in High-Grade Glioma Drug Details: RQNestin-34.5v.2 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CAN-3110 in Recurrent Glioblastoma Multiforme (GBM)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CAN-3110 in Recurrent Glioblastoma Multiforme (GBM) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CAN-3110 in Recurrent Glioblastoma Multiforme (GBM) Drug Details: RQNestin-34.5v.2 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pemigatinib in Astrocytoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pemigatinib in Astrocytoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pemigatinib in Astrocytoma Drug Details: Pemigatinib (Pemazyre) is acts as an anti neoplastic...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Aglatimagene Besadenovec in Prostate Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Aglatimagene Besadenovec in Prostate Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Aglatimagene Besadenovec in Prostate Cancer Drug Details: aglatimagene besadenovec is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Aglatimagene Besadenovec in High-Grade Glioma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Aglatimagene Besadenovec in High-Grade Glioma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Aglatimagene Besadenovec in High-Grade Glioma Drug Details: Aglatimagene besadenovec is...